Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Delcath Systems Inc (NQ: DCTH )

11.80 -0.47 (-3.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 282,839
Open 12.32
Bid (Size) 12.00 (5)
Ask (Size) 12.11 (41)
Prev. Close 12.27
Today's Range 11.77 - 12.38
52wk Range 3.100 - 12.88
Shares Outstanding 7,906,728
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire

Performance

YTD
+187.45%
+187.45%
1 Month
+21.65%
+21.65%
3 Month
+20.29%
+20.29%
6 Month
+59.03%
+59.03%
1 Year
+263.64%
+263.64%

More News

Read More
Uncovering Potential: Delcath Systems's Earnings Preview
Via Benzinga
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Host Third Quarter 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
Analyst Scoreboard: 4 Ratings For Delcath Systems
Via Benzinga
Assessing Delcath Systems: Insights From 4 Financial Analysts
Via Benzinga
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
From Delcath Systems, Inc.
Via Business Wire
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups
From Delcath Systems, Inc.
Via Business Wire
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
Via Benzinga
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress
From Delcath Systems, Inc.
Via Business Wire
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
DCTH Stock Earnings: Delcath Systems Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Host Second Quarter 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
Have $5-10? 7 Affordable Stocks That Are About to Breakout.
Via InvestorPlace
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors
From Delcath Systems, Inc.
Via Business Wire
Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.